| Dr Bradley Bohnstedt, MD | |
|
355 W 16th St Ste 5100, Indianapolis, IN 46202-2274 | |
| (317) 963-1300 | |
| Not Available |
| Full Name | Dr Bradley Bohnstedt |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 17 Years |
| Location | 355 W 16th St Ste 5100, Indianapolis, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952568271 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Indiana University Health | Indianapolis, IN | Hospital |
| Iu Health West Hospital | Avon, IN | Hospital |
| Indiana University Health Bloomington Hospital | Bloomington, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Family Physicians, Inc. | 7911992797 | 424 |
News Archive
Yale researchers investigating the genetic causes of blood pressure variation have identified a previously undescribed syndrome associated with seizures, a lack of coordination, developmental delay and hearing loss.
Scientists at Jefferson Medical College have received a four-year, $3 million National Institutes of Health grant funded by the National Heart, Lung and Blood Institute to study variations of platelet function, specifically, the genetics of platelet gene expression. The study aims to find data that can be translated into novel therapeutic strategies and develop better predictors of cardiovascular disease.
Mylan Inc. has announced that its subsidiary Alphapharm Pty Limited won a favorable decision in patent litigation against it and Barr Laboratories Inc. relating to Galantamine Tablets, USP, the generic version of Ortho-McNeil's Razadyne Tablets, 4 mg, 8 mg and 12 mg.
Even with the health law's future in question, news reports indicate that some states are pressing forward with implementation, while another - Massachusetts - considers itself untouched by what becomes of the federal law. All the while, the politics of the health overhaul will play a significant role at the state level, too.
Increased uptake of recombinant therapies and prophylactic use, coupled with improved diagnosis of haemophilia, is expected to drive the associated therapeutics market. Recombinant therapies are likely to command a premium price and fuel growth in developed markets, while heightened access to treatment and larger patient volumes due to more funding for critical care are anticipated to contribute to demand in emerging markets.
› Verified 6 days ago
| Entity Name | University Family Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043275787 PECOS PAC ID: 7911992797 Enrollment ID: O20040420000393 |
News Archive
Yale researchers investigating the genetic causes of blood pressure variation have identified a previously undescribed syndrome associated with seizures, a lack of coordination, developmental delay and hearing loss.
Scientists at Jefferson Medical College have received a four-year, $3 million National Institutes of Health grant funded by the National Heart, Lung and Blood Institute to study variations of platelet function, specifically, the genetics of platelet gene expression. The study aims to find data that can be translated into novel therapeutic strategies and develop better predictors of cardiovascular disease.
Mylan Inc. has announced that its subsidiary Alphapharm Pty Limited won a favorable decision in patent litigation against it and Barr Laboratories Inc. relating to Galantamine Tablets, USP, the generic version of Ortho-McNeil's Razadyne Tablets, 4 mg, 8 mg and 12 mg.
Even with the health law's future in question, news reports indicate that some states are pressing forward with implementation, while another - Massachusetts - considers itself untouched by what becomes of the federal law. All the while, the politics of the health overhaul will play a significant role at the state level, too.
Increased uptake of recombinant therapies and prophylactic use, coupled with improved diagnosis of haemophilia, is expected to drive the associated therapeutics market. Recombinant therapies are likely to command a premium price and fuel growth in developed markets, while heightened access to treatment and larger patient volumes due to more funding for critical care are anticipated to contribute to demand in emerging markets.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bradley Bohnstedt, MD 250 N Shadeland Ave, Indianapolis, IN 46219-4959 Ph: () - | Dr Bradley Bohnstedt, MD 355 W 16th St Ste 5100, Indianapolis, IN 46202-2274 Ph: (317) 963-1300 |
News Archive
Yale researchers investigating the genetic causes of blood pressure variation have identified a previously undescribed syndrome associated with seizures, a lack of coordination, developmental delay and hearing loss.
Scientists at Jefferson Medical College have received a four-year, $3 million National Institutes of Health grant funded by the National Heart, Lung and Blood Institute to study variations of platelet function, specifically, the genetics of platelet gene expression. The study aims to find data that can be translated into novel therapeutic strategies and develop better predictors of cardiovascular disease.
Mylan Inc. has announced that its subsidiary Alphapharm Pty Limited won a favorable decision in patent litigation against it and Barr Laboratories Inc. relating to Galantamine Tablets, USP, the generic version of Ortho-McNeil's Razadyne Tablets, 4 mg, 8 mg and 12 mg.
Even with the health law's future in question, news reports indicate that some states are pressing forward with implementation, while another - Massachusetts - considers itself untouched by what becomes of the federal law. All the while, the politics of the health overhaul will play a significant role at the state level, too.
Increased uptake of recombinant therapies and prophylactic use, coupled with improved diagnosis of haemophilia, is expected to drive the associated therapeutics market. Recombinant therapies are likely to command a premium price and fuel growth in developed markets, while heightened access to treatment and larger patient volumes due to more funding for critical care are anticipated to contribute to demand in emerging markets.
› Verified 6 days ago
Kenneth Adam Moore, MD Neurological Surgery Medicare: May Accept Medicare Assignments Practice Location: 355 W 16th St Ste 5100, Indianapolis, IN 46202 Phone: 317-963-1300 Fax: 317-222-2012 | |
Dr. Gordon Guanxiong Mao, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 355 W. 16th Street, Goodman Hall Suite 5100, Indianapolis, IN 46202 Phone: 317-963-1300 | |
Ajay Patel, Neurological Surgery Medicare: Medicare Enrolled Practice Location: 355 W 16th St Ste 5100, Indianapolis, IN 46202 Phone: 317-396-1234 | |
James Christopher Miller, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 355 W 16th St, Suite 5100, Indianapolis, IN 46202 Phone: 317-396-1300 Fax: 317-924-8472 | |
Dr. Michael B Pritz, M.D. Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 1801 N Senate Blvd, Suite 535, Indianapolis, IN 46202 Phone: 317-396-1300 Fax: 317-396-1346 | |
Monica C Wehby, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 8402 Harcourt Rd Ste 830, Indianapolis, IN 46260 Phone: 317-396-1300 Fax: 317-352-3408 | |
Ian Kainoa White, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1801 N Senate Blvd, Suite 535, Indianapolis, IN 46202 Phone: 317-396-1234 |